The subcutaneous version, dubbed Leqembi Iqlik, is approved as a maintenance treatment that can be used after an initial intravenous infusion regimen.

The drug, designed to target mesothelin-related cancers, had dose-limiting toxicities apparently related to its mechanism.

Previously, the two companies came together to test palazestrant, a selective estrogen receptor degrader, with Ibrance.

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

The biotech firm launched the Phase Ib trial of Tune-401 in New Zealand and Hong Kong, making it the first pipeline candidate to enter clinical trials.

Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...

The Phase II trial could provide registrational data on Treos' peptide immunotherapy and Junshi's PD-1 inhibitor in MSS colorectal cancer.

Aster adds a longitudinal dataset from more than 400,000 cancer patients to Zephyr's AI and omics capabilities.

Kyverna is pursuing myasthenia gravis as a second indication for KYV-101 after stiff-person syndrome, for which it has already launched a pivotal study.

Not all patients are able to access the battery of tumor sequencing, liquid biopsy, and immunohistochemistry testing needed to assess HER2 biomarkers.

Collaborators from various institutions will leverage the latest multidisciplinary drug development tools to produce tailored treatment and prevention strategies.

Based on preliminary Phase I data from 21 patients, the firm hopes to eventually pursue accelerated approval for MT-601.